Quantcast

Industry news that matters to you.  Learn more

Archives for May 2016

Astellas, Daiichi Sankyo, and Takeda Announce Research Collaboration on Establishing Biomarker Database on Healthy Adults

Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka; Headquarters: Tokyo; TSE: 4503; “Astellas”), Daiichi Sankyo Company, Limited (President and CEO: Joji Nakayama; Headquarters: Tokyo; TSE: 4568; “Daiichi Sankyo”), and Takeda Pharmaceutical Company Limited (President and CEO: Christophe Weber; Headquarters: Osaka; TSE: 4502; “Takeda”) recently announced that they have entered into a joint research agreement. It is an agreement to comprehensively acquire and analyze fundamental biomarker*1 data on healthy adult volunteers in order to optimize and accelerate the development of innovative medicines.

Illumina Selects BioDiscovery’s NxClinical Software for Data Visualization, Management and Interpretation for its CytoSeq ™ assay, an NGS-based Solution for Detection of CNVs, AOH, and SNVs

BioDiscovery, Inc., a leader in innovative genomic data analysis software solutions recently announced a collaborative agreement with Illumina Inc. (NASDAQ: ILMN) to provide BioDiscovery’s NxClinical software as the secondary data analysis and management tool for Illumina’s CytoSeq™ assay. The NxClinical software will be offered with the CytoSeq product to provide an easy-to-use interactive tool for visualization and interpretation of genomic events.

LabCorp Announces the Launch of the Epi proColon Test for Colorectal Cancer Screening

Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced the launch of Epi proColon®, a blood-based test for colorectal cancer screening that was approved on April 13, 2016 for clinical use by the U.S. Food and Drug Administration (FDA). Epi proColon® is the first FDA-approved DNA based blood test for colorectal cancer. The test was developed by Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) and is available under a joint commercialization agreement with Polymedco, Inc. in North America. LabCorp, the world’s leading healthcare diagnostics company, is the first laboratory in the U.S. to offer this FDA-approved, blood-based colorectal cancer screening test.